SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

SpaceXs agreement to acquire low-band spectrum for Starlink Mobile has raised concerns about future competition and weighed heavily on T-Mobile shares. Traders are split between viewing Starlink as a long-term threat and calling the selloff an overreaction, arguing that building a competitive network will take substantial time and infrastructure.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

SpaceXs agreement to acquire low-band spectrum for Starlink Mobile has intensified concerns about future competition, weighing on AT&T and other major wireless carriers. Traders are split between viewing the sharp selloff as an overreaction given the time and infrastructure needed to build a rival network and seeing a credible long-term threat; some are buying the dip for AT&Ts dividend.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax rallied alongside vaccine peers after reports of an NIH push to accelerate personalized cancer vaccines, with traders noting the move was largely sector-wide sympathy buying rather than a company-specific oncology announcement. The community also debated whether heavy short interest could amplify the move, while some pointed to Sanofis combination-vaccine trial as a separate potential catalyst.

Chevron Corporation. The Group's principal activities are providing administrative, financial and management support for fully integrated petroleum, chemicals and coal mining operations. Exploration and production operations consist of exploring, developing and producing crude oil and natural gas and marketing natural gas. Refining, marketing and transportation operations relate to refining crude oil into finished petroleum products, marketing crude oil, natural gas and transporting crude oil, natural gas and petroleum products. Chemical operations include manufacture and marketing of commodity petrochemicals, plastics for industrial uses and fuel and lubricant oil additives. The Other operations consist of coal mining operations, power generation business, worldwide cash management and debt financing activities, corporate administrative functions, insurance operations, real estate activities and technology companies.

Chevron Corp.

Middle East conflict and Strait of Hormuz supply risks are driving discussion of higher, volatile oil prices and Chevrons sensitivity to crude; traders debate whether the oil rally will translate into further gains for CVX or whether easing tensions and pullbacks in crude will weigh on shares. Chevrons planned Venezuela expansion is also discussed as a longer-term growth opportunity, with execution and political risks noted.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

Trumps claimed deal for Russian diesel supplies is prompting discussion about added fuel supply and possible downward pressure on oil, while ongoing Middle East supply risks keep some traders bullish. Reactions are mixed, with traders debating whether the potential supply increase outweighs geopolitical disruptions.

Zoracles

A sharp, high-volume rebound after a prolonged slide has sparked momentum and short-squeeze speculation, though traders disagree over whether the move can hold or is another brief pump. Some are also debating whether Zoras expansion into Solana-based attention markets could benefit the token, but the messages do not establish a confirmed catalyst for the surge.

AGNC Investment Corp. engages in the operation of a real estate investment trust. The firm invests in residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by the United States government-sponsored enterprise or by the United States government agency. It also invests in other types of mortgage and mortgage-related securities, such as credit risk transfer securities and non-Agency residential and commercial mortgage-backed securities, where repayment of principal and interest is not guaranteed by the United States government-sponsored enterprise or by the United States Government agency, and other assets related to the housing, mortgage, or real estate markets. The company was founded on January 7, 2008 and is headquartered in Bethesda, MD.

AGNC Investment Corp

AGNC is drawing attention amid a sharp selloff in rate-sensitive mortgage REITs, which traders link to rising Treasury yields and mortgage-backed-securities repricing that could pressure book value and earnings. Some holders fear a dividend cut and see further downside, while income-focused investors are buying the dip for its monthly dividend and viewing the decline as an oversold opportunity.

Sunrun, Inc. engages in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems. It sells solar service offerings and installs solar energy systems for homeowners. Customers can access its products through three channels: direct-to-consumer, solar partnerships, and strategic partnerships. The company was founded by Edward Harris Fenster, Robert Nat Kreamer, and Lynn Michelle Jurich in January 2007 and is headquartered in San Francisco, CA.

Sunrun Inc

Sunruns distributed AI-computing pilot, which would use customers solar-and-battery-equipped homes to host computing nodes, is driving attention and enthusiasm about a new data-center power opportunity. Traders are debating whether the concept can generate meaningful revenue, since the rollout is early and its economics remain unclear.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

Exchange-delisting concerns are fueling bearish discussion, with traders debating the significance of Upbit and other platform changes; some holders argue the changes are limited or being mischaracterized. Bulls counter with JasmyChain activity and ecosystem partnerships as signs of development, while acknowledging that real adoption and token demand remain unproven.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is rallying to fresh highs amid strength in software stocks, with traders highlighting its breakout and momentum. Bulls point to AI-related observability demand, while skeptics warn that the valuation is stretched and the move could reverse.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's Why Exelixis (EXEL) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Exelixis (EXEL) is a Top-Ranked Growth Stock: Should You Buy?

Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans?

Exelixis faces a three-month FDA review delay for zanzalintinib, pushing the potential CRC decision to March 2027.

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Alpha Teknova (TKNO) Moves 7.1% Higher: Will This Strength Last?

Alpha Teknova (TKNO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Exelixis (EXEL) is a Strong Growth Stock

EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review — William Blair Sees More Swings In Near Term

Equity

The FDA told Exelixis on Thursday that it had extended the review of a new drug application for zanzalintinib plus Roche’s Tecentriq in patients whose colorectal cancer has spread. 

Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In

FDA extends Exelixis NDA review for zanzalintinib to March 2027. Analyst evaluates stock volatility and revenue outlook.read more...

Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Exelixis Inc

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$59.86
Prev Close	$59.02
Open	$59.00
Dividend Yield	0.00%
50-Day Moving Average	$56.14
Beta	0.49
Avg. Volume	2.22M
PE Ratio	18.80

52-Week High	$61.14
52-Week Low	$33.76
Market Capitalization	$14.62B
EPS (Annual)	$2.78
Price to Book	8.08
Revenue Per Employee	$2.15M

Feed

News

Sentiment

Earnings

Fundamentals

Info

EXEL Fundamentals